Affinia Therapeutics Inc. has filed a notice of an exempt offering of securities to raise $45 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Affinia Therapeutics Inc. is raising up to $45,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Affinia Therapeutics Inc.
We are a team with decades of proven success in translating science from bench to bedside across many companies and medicines, in gene therapy and beyond. We are driven by a purpose: to make a lasting positive impact in the lives of people affected by devastating rare and prevalent diseases where the genetic cause is understood. Our thesis is simple and our vision, clear: gene therapies have an immense potential to cure many diseases with a one-time dose, but they are limited by current delivery methods for the genetic payload. We formed Affinia Therapeutics to singularly focus on creating innovations that can expand the reach of gene therapies to more prevalent diseases. Were re-engineering the adeno-associated virus (AAV), a gene therapy delivery method that has shown promise but only in a small number of diseases.
To learn more about Affinia Therapeutics Inc., visit https://affiniatx.com/
Affinia Therapeutics Inc. Linkedin Page: https://www.linkedin.com/company/affinia-therapeutics/
Contact:
Rick Modi, Chief Executive Officer
617-430-7817
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
